Fig. 3: Subgroup analysis of progression-free survival (PFS) assessed by Investigator in the intent-to-treat population (n = 275 patients). | Nature Communications

Fig. 3: Subgroup analysis of progression-free survival (PFS) assessed by Investigator in the intent-to-treat population (n = 275 patients).

From: Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial

Fig. 3: Subgroup analysis of progression-free survival (PFS) assessed by Investigator in the intent-to-treat population (n = 275 patients).

HRs are for lerociclib versus placebo. PFS HRs are indicated by diamonds and 95% CIs are indicated by the crossing horizontal lines. Diamond size is proportional to the sample size of each patient subgroup. HRs were estimated based on the unstratified Cox proportional hazards model for the stratification factor related subgroups including menopausal status, visceral metastasis, liver metastasis; stratified Cox proportional hazards model for other subgroups and overall HR. ECOG Eastern Cooperative Oncology Group, ER estrogen receptor, HR hazard ratio, PR progesterone receptor. Source data are provided as a Source Data file.

Back to article page